Genetic susceptibility to rheumatoid arthritis and its implications for novel drug discovery

Expert Opinion on Drug Discovery

Volumn 11, Issue 8, 2016, Pages 805-813

  Yarwood, Annie ^a   Eyre, Steve ^a   Worthington, Jane ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Drug discovery; functional genomics; genetics; rheumatoid arthritis; therapeutic target

Indexed keywords

ABATACEPT; ANTIRHEUMATIC AGENT; METHOTREXATE; RITUXIMAB; SIRUKUMAB; TOCILIZUMAB; TOFACITINIB;

CHROMATIN; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; DISEASE COURSE; DNA CONFORMATION; GAIN OF FUNCTION MUTATION; GENE EXPRESSION; GENE FUNCTION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMAN; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVIEW; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; ANIMAL; ARTHRITIS, RHEUMATOID; DRUG DESIGN; DRUG DEVELOPMENT; GENETIC PREDISPOSITION; GENETICS; MOLECULARLY TARGETED THERAPY; PROCEDURES;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG DESIGN; DRUG DISCOVERY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MOLECULAR TARGETED THERAPY;

EID: 84978872739     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1080/17460441.2016.1195366     Document Type: Review

References (54)

1. P.Barrera, A.van der Maas, A.E.van Ede, et al. Drug survival, efficacy and toxicity of monotherapy with a fully human anti-tumour necrosis factor-alpha antibody compared with methotrexate in long-standing rheumatoid arthritis. Rheumatology (Oxford). 2002;41(4):430–439.
2. W.G.Dixon, K.L.Hyrich, K.D.Watson, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis. 2010;69(3):522–528. doi:10.1136/ard.2009.118935.
3. M.J.Coenen, E.J.Toonen, H.Scheffer, et al. Pharmacogenetics of anti-TNF treatment in patients with rheumatoid arthritis. Pharmacogenomics. 2007;8(7):761–773. doi:10.1038/ng.3286.
4. M.R.Nelson, H.Tipney, J.L.Painter, et al. The support of human genetic evidence for approved drug indications. Nat Genet. 2015;47(8):856–860. doi:10.1038/ng.3314.• This paper provides support for the use of genetics in drug discovery.
5. D.Cook, D.Brown, R.Alexander, et al. Lessons learned from the fate of AstraZeneca’s drug pipeline: a five-dimensional framework. Nat Rev Drug Discov. 2014;13(6):419–431. doi:10.1038/nrd4309.
6. S.Eyre, J.Bowes, D.Diogo, et al. High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis. Nat Genet. 2012;44:1336–1340. doi:10.1038/ng.2462.
7. K.McAllister, A.Yarwood, J.Bowes, et al. Identification of BACH2 and RAD51B as rheumatoid arthritis susceptibility loci in a meta-analysis of genome-wide data. Arthritis Rheum. 2013;65:3058–3062. doi:10.1002/art.38183.
8. Y.Okada, D.Wu, G.Trynka, et al. Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature. 2014;506(7488):376–381. doi:10.1038/nature12873.•• A large scale GWAS and meta analysis of RA, which utilises a bioinformatic pipeline to combine GWAS results with biological and pathway data. The authors conduct a high throughput drug screen to identify drug targets from GWAS results providing proof of concept for the utility of genetics in drug discovery.
9. A.Barski, S.Cuddapah, K.Cui, et al. High-resolution profiling of histone methylations in the human genome. Cell. 2007;129(4):823–837. doi:10.1016/j.cell.2007.05.009.
10. T.C.Messemaker, T.W.Huizinga, F.Kurreeman Immunogenetics of rheumatoid arthritis: understanding functional implications. J Autoimmun. 2015;64:74–81. doi:10.1016/j.jaut.2015.07.007.
11. G.Li, D.Diogo, D.Wu, et al. Human genetics in rheumatoid arthritis guides a high-throughput drug screen of the CD40 signaling pathway. PLoS Genet. 2013;9:e1003487. doi:10.1371/journal.pgen.1003487.• A systematic study of the CD40 locus associated with RA. The authors use eQTL and perturbation studies to show direct correlation between associated variants, gene expression and cell surface protein expression. A high throughput drug screen identifies potential therapeutic inhibitors.
12. N.Nishimoto. Interleukin-6 in rheumatoid arthritis. Curr Opin Rheumatol. 2006;18(3):277–281. doi:10.1097/01.bor.0000218949.19860.d1.
13. J.S.Smolen, M.E.Weinblatt, S.Sheng, et al. Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis. 2014;73(9):1616–1625. doi:10.1136/annrheumdis-2013-205137.
14. M.H.Shaw, V.Boyartchuk, S.Wong, et al. A natural mutation in the Tyk2 pseudokinase domain underlies altered susceptibility of B10.Q/J mice to infection and autoimmunity. Proc Natl Acad Sci U S A. 2003;100(20):11594–11599. doi:10.1073/pnas.1930781100.
15. R.M.Plenge, E.M.Scolnick, D.Altshuler. Validating therapeutic targets through human genetics. Nat Rev Drug Discov. 2013;12(8):581–594. doi:10.1038/nrd4051.
16. A.J.The. $2.6 billion pill–methodologic and policy considerations. N Engl J Med. 2015;372(20):1877–1879. doi:10.1056/NEJMp1500848.
17. M.S.Brown, J.L.Goldstein. Expression of the familial hypercholesterolemia gene in heterozygotes: mechanism for a dominant disorder in man. Science. 1974;185(4145):61–63.
18. D.J.Rader, J.Cohen, H.H.Hobbs. Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. J Clin Invest. 2003;111(12):1795–1803. doi:10.1172/JCI18925.
19. M.Abifadel, M.Varret, J.P.Rabes, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34(2):154–156. doi:10.1038/ng1161.
20. J.Cohen, A.Pertsemlidis, I.K.Kotowski, et al. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet. 2005;37(2):161–165. doi:10.1038/ng1509.
21. I.K.Kotowski, A.Pertsemlidis, A.Luke, et al. A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol. Am J Hum Genet. 2006;78(3):410–422. doi:10.1086/500615.
22. J.C.Cohen, E.Boerwinkle, T.H.MosleyJr., et al. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354(12):1264–1272. doi:10.1056/NEJMoa054013.
23. K.N.Maxwell, J.L.Breslow. Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proc Natl Acad Sci U S A. 2004;101(18):7100–7105. doi:10.1073/pnas.0402133101.
24. S.W.Park, Y.-A.Moon, J.D.Horton. Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver. J Biol Chem. 2004;279(48):50630–50638. doi:10.1074/jbc.M410077200.
25. E.A.Stein, S.Mellis, G.D.Yancopoulos, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med. 2012;366(12):1108–1118. doi:10.1056/NEJMoa1105803.
26. A.P.Gregory, C.A.Dendrou, K.E.Attfield, et al. TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis. Nature. 2012;488(7412):508–511. doi:10.1038/nature11307.
27. I.C.Scott, S.D.Seegobin, S.Steer, et al. Predicting the risk of rheumatoid arthritis and its age of onset through modelling genetic risk variants with smoking. PLoS Genet. 2013;9:e1003808. doi:10.1371/journal.pgen.1003808.• Uses genetics to attempt to predict RA.
28. A.Yarwood, B.Han, S.Raychaudhuri, et al. A weighted genetic risk score using all known susceptibility variants to estimate rheumatoid arthritis risk. Ann Rheum Dis. 2013. doi: 10.1136/annrheumdis-2013-eular.538.• Uses genetics to attempt to predict RA.
29. N.A.Daha, R.E.Toes. Rheumatoid arthritis: are ACPA-positive and ACPA-negative RA the same disease? Nat Rev Rheumatol. 2011;7:202–203. doi:10.1038/nrrheum.2011.28.
30. A.H.van der Helm-van Mil, T.W.Huizinga. Advances in the genetics of rheumatoid arthritis point to subclassification into distinct disease subsets. Arthritis Res Ther. 2008;10:205. doi:10.1186/ar2384.
31. S.Viatte, D.Plant, B.Han, et al. Association of HLA-DRB1 haplotypes with rheumatoid arthritis severity, mortality, and treatment response. JAMA. 2015;313(16):1645–1656. doi:10.1001/jama.2015.3435.
32. B.Han, D.Diogo, S.Eyre, et al. Fine mapping seronegative and seropositive rheumatoid arthritis to shared and distinct HLA alleles by adjusting for the effects of heterogeneity. Am J Hum Genet. 2014;94:522–532. doi:10.1016/j.ajhg.2014.02.013.
33. D.van der Woude, J.J.Houwing-Duistermaat, R.E.Toes, et al. Quantitative heritability of anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis. Arthritis Rheum. 2009;60:916–923. doi:10.1002/art.24385.
34. S.Viatte, D.Plant, J.Bowes, et al. Genetic markers of rheumatoid arthritis susceptibility in anti-citrullinated peptide antibody negative patients. Ann Rheum Dis. 2012;71:1984–1990. doi:10.1136/annrheumdis-2011-201225.
35. L.O.Reuther, B.Vainer, J.Sonne, et al. Thiopurine methyltransferase (TPMT) genotype distribution in azathioprine-tolerant and -intolerant patients with various disorders. The impact of TPMT genotyping in predicting toxicity. Eur J Clin Pharmacol. 2004;59(11):797–801. doi:10.1007/s00228-003-0698-8.• An example of where genetics is used in clinic to inform treatment.
36. A.Finckh, M.H.Liang, C.M.van Herckenrode, et al. Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: a meta-analysis. Arthritis Rheum. 2006;55(6):864–872. doi:10.1002/art.22353.
37. C.A.Scire, S.M.Verstappen, H.Mirjafari, et al. Reduction of long-term disability in inflammatory polyarthritis by early and persistent suppression of joint inflammation: results from the Norfolk arthritis register. Arthritis Care Res (Hoboken). 2011;63(7):945–952. doi:10.1002/acr.20453.
38. C.A.Scire, M.Lunt, T.Marshall, et al. Early remission is associated with improved survival in patients with inflammatory polyarthritis: results from the Norfolk arthritis register. Ann Rheum Dis. 2014;73(9):1677–1682. doi:10.1136/annrheumdis-2013-203339.
39. J.Cui, E.A.Stahl, S.Saevarsdottir, et al. Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis. PLoS Genet. 2013;9(3):e1003394. doi:10.1371/journal.pgen.1003394.
40. I.Acosta-Colman, N.Palau, J.Tornero, et al. GWAS replication study confirms the association of PDE3A-SLCO1C1 with anti-TNF therapy response in rheumatoid arthritis. Pharmacogenomics. 2013;14(7):727–734. doi:10.2217/pgs.13.60.
41. K.Musunuru, A.Strong, M.Frank-Kamenetsky, et al. From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus. Nature. 2010;466:714–719. doi:10.1038/nature09266.• An example of a non-coding variant directly affecting disease phenotype.
42. B.P.Fairfax, S.Makino, J.Radhakrishnan, et al. Genetics of gene expression in primary immune cells identifies cell type-specific master regulators and roles of HLA alleles. Nat Genet. 2012;44:502–510. doi:10.1038/ng.2205.
43. A.H.Lango, K.Estrada, G.Lettre, et al. Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature. 2010;467(7317):832–838. doi:10.1038/nature09410.
44. A.C.Nica, S.B.Montgomery, A.S.Dimas, et al. Candidate causal regulatory effects by integration of expression QTLs with complex trait genetic associations. PLoS Genet. 2010;6:e1000895. doi:10.1371/journal.pgen.1000895.
45. D.L.Nicolae, E.Gamazon, W.Zhang, et al. Trait-associated SNPs are more likely to be eQTLs: annotation to enhance discovery from GWAS. PLoS Genet. 2010;6:e1000888. doi:10.1371/journal.pgen.1000888.
46. B.P.Fairfax, P.Humburg, S.Makino, et al. Innate immune activity conditions the effect of regulatory variants upon monocyte gene expression. Science. 2014;343:1246949. doi:10.1126/science.1246949.• This study highlights the importance of identifying the cell type in which your variant of interest exerts its effects showing the presence of response QTLs in monocytes.
47. M.N.Lee, C.Ye, A.C.Villani, et al. Common genetic variants modulate pathogen-sensing responses in human dendritic cells. Science. 2014;343:1246980. doi:10.1126/science.1246980.• This study highlights the importance of identifying the cell type in which your variant of interest exerts its effects showing the presence of response QTLs in dendritic cells.
48. L.J.Davison, C.Wallace, J.D.Cooper, et al. Long-range DNA looping and gene expression analyses identify DEXI as an autoimmune disease candidate gene. Hum Mol Genet. 2012;21:322–333. doi:10.1093/hmg/ddr468.• an example of a long range interaction, where disease susceptibility variants in CLEC16A act on a neighboring gene, DEXI.
49. N.H.Dryden, L.R.Broome, F.Dudbridge, et al. Unbiased analysis of potential targets of breast cancer susceptibility loci by capture Hi-C. Genome Res. 2014;24(11):1854–1868. doi:10.1101/gr.175034.114.
50. R.Jager, G.Migliorini, M.Henrion, et al. Capture Hi-C identifies the chromatin interactome of colorectal cancer risk loci. Nat Commun. 2015;19:6178. doi:10.1038/ncomms7178.
51. B.Mifsud, F.Tavares-Cadete, A.N.Young, et al. Mapping long-range promoter contacts in human cells with high-resolution capture Hi-C. Nat Genet. 2015;47(6):598–606.
52. P.Martin, A.McGovern, G.Orozco, et al. Capture Hi-C reveals novel candidate genes and complex long-range interactions with related autoimmune risk loci. Nat Commun. 2015;6:10069. doi:10.1038/ncomms10069.•• The first publication to systematically investigate the potential interaction between the disease associated variants of four autoimmune diseases and their functional target genes. The study has redefined the way candidate genes are allocated to genetic loci and demonstrated that loci from different disease can interact with a common regulatory element.
53. Y.Wu, D.Liang, Y.Wang, et al. Correction of a genetic disease in mouse via use of CRISPR-Cas9. Cell Stem Cell. 2013;13(6):659–662. doi:10.1016/j.stem.2013.10.016.•• CRISPR is used to correct a mutation in mice which causes cataracts. The corrected allele was shown to be passes on to offspring. Provides proof of concept for correction for single gene disorders using CRISPR.
54. G.Schwank, B.K.Koo, V.Sasselli, et al. Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. Cell Stem Cell. 2013;13(6):653–658. doi:10.1016/j.stem.2013.11.002.